128 related articles for article (PubMed ID: 12120997)
1. Alphavirus replicon particles as candidate HIV vaccines.
Davis NL; West A; Reap E; MacDonald G; Collier M; Dryga S; Maughan M; Connell M; Walker C; McGrath K; Cecil C; Ping LH; Frelinger J; Olmsted R; Keith P; Swanstrom R; Williamson C; Johnson P; Montefiori D; Johnston RE
IUBMB Life; 2002; 53(4-5):209-11. PubMed ID: 12120997
[TBL] [Abstract][Full Text] [Related]
2. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
[TBL] [Abstract][Full Text] [Related]
3. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development.
Williamson C; Morris L; Maughan MF; Ping LH; Dryga SA; Thomas R; Reap EA; Cilliers T; van Harmelen J; Pascual A; Ramjee G; Gray G; Johnston R; Karim SA; Swanstrom R
AIDS Res Hum Retroviruses; 2003 Feb; 19(2):133-44. PubMed ID: 12639249
[TBL] [Abstract][Full Text] [Related]
4. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF
Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.
Johnston RE; Johnson PR; Connell MJ; Montefiori DC; West A; Collier ML; Cecil C; Swanstrom R; Frelinger JA; Davis NL
Vaccine; 2005 Oct; 23(42):4969-79. PubMed ID: 16005121
[TBL] [Abstract][Full Text] [Related]
6. Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon.
Lee JS; Dyas BK; Nystrom SS; Lind CM; Smith JF; Ulrich RG
J Infect Dis; 2002 Apr; 185(8):1192-6. PubMed ID: 11930333
[TBL] [Abstract][Full Text] [Related]
7. The development of HIV-1 subtype C vaccines for Southern Africa.
Williamson AL
IUBMB Life; 2002; 53(4-5):207-8. PubMed ID: 12120996
[TBL] [Abstract][Full Text] [Related]
8. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.
Perri S; Greer CE; Thudium K; Doe B; Legg H; Liu H; Romero RE; Tang Z; Bin Q; Dubensky TW; Vajdy M; Otten GR; Polo JM
J Virol; 2003 Oct; 77(19):10394-403. PubMed ID: 12970424
[TBL] [Abstract][Full Text] [Related]
9. A single-site mutant and revertants arising in vivo define early steps in the pathogenesis of Venezuelan equine encephalitis virus.
Aronson JF; Grieder FB; Davis NL; Charles PC; Knott T; Brown K; Johnston RE
Virology; 2000 Apr; 270(1):111-23. PubMed ID: 10772984
[TBL] [Abstract][Full Text] [Related]
10. Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors.
Vasilakis N; Falvey D; Gangolli SS; Coleman J; Kowalski J; Udem SA; Zamb TJ; Kovacs GR
Nat Biotechnol; 2003 Aug; 21(8):932-5. PubMed ID: 12845329
[TBL] [Abstract][Full Text] [Related]
11. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.
White LJ; Parsons MM; Whitmore AC; Williams BM; de Silva A; Johnston RE
J Virol; 2007 Oct; 81(19):10329-39. PubMed ID: 17652394
[TBL] [Abstract][Full Text] [Related]
12. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection.
Schleiss MR; Lacayo JC; Belkaid Y; McGregor A; Stroup G; Rayner J; Alterson K; Chulay JD; Smith JF
J Infect Dis; 2007 Mar; 195(6):789-98. PubMed ID: 17299708
[TBL] [Abstract][Full Text] [Related]
13. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1.
Davis NL; Brown KW; Greenwald GF; Zajac AJ; Zacny VL; Smith JF; Johnston RE
Virology; 1995 Sep; 212(1):102-10. PubMed ID: 7676619
[TBL] [Abstract][Full Text] [Related]
14. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
15. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
Dong M; Zhang PF; Grieder F; Lee J; Krishnamurthy G; VanCott T; Broder C; Polonis VR; Yu XF; Shao Y; Faix D; Valente P; Quinnan GV
J Virol; 2003 Mar; 77(5):3119-30. PubMed ID: 12584337
[TBL] [Abstract][Full Text] [Related]
16. Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.
Fluet ME; Whitmore AC; Moshkoff DA; Fu K; Tang Y; Collier ML; West A; Moore DT; Swanstrom R; Johnston RE; Davis NL
Virology; 2008 Jan; 370(1):22-32. PubMed ID: 17904185
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.
Gupta S; Janani R; Bin Q; Luciw P; Greer C; Perri S; Legg H; Donnelly J; Barnett S; O'Hagan D; Polo JM; Vajdy M
J Virol; 2005 Jun; 79(11):7135-45. PubMed ID: 15890953
[TBL] [Abstract][Full Text] [Related]
19. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine.
Ljungberg K; Whitmore AC; Fluet ME; Moran TP; Shabman RS; Collier ML; Kraus AA; Thompson JM; Montefiori DC; Beard C; Johnston RE
J Virol; 2007 Dec; 81(24):13412-23. PubMed ID: 17913817
[TBL] [Abstract][Full Text] [Related]
20. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
Greer CE; Zhou F; Goodsell A; Legg HS; Tang Z; zur Megede J; Uematsu Y; Polo JM; Vajdy M
Scand J Immunol; 2007 Dec; 66(6):645-53. PubMed ID: 17944814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
